Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

94.4%

+7.9% vs industry average

Late-Stage Pipeline

50%

10 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
10(50.0%)
Phase 3
10(50.0%)
20Total
Phase 1(10)
Phase 3(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT07475572Phase 1Recruiting

Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Role: lead

NCT07489131Phase 3Recruiting

Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema

Role: lead

NCT06732804Phase 1Completed

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio

Role: lead

NCT06570772Phase 3Terminated

Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio

Role: lead

NCT05395091Phase 3Completed

Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND

Role: lead

NCT05632211Phase 1Completed

A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants

Role: lead

NCT05876949Phase 1Completed

AVT03 With Xgeva in Healthy Male Subjects

Role: lead

NCT05986786Phase 3Completed

Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease

Role: lead

NCT06400719Phase 1Completed

Pilot Study of AVT16 in Healthy Adult Subjects

Role: lead

NCT05842213Phase 3Completed

Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX

Role: lead

NCT05155293Phase 3Completed

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

Role: lead

NCT05126784Phase 1Completed

AVT03 With Prolia in Healthy Male Subjects

Role: lead

NCT04930042Phase 3Completed

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

Role: lead

NCT04744363Phase 1Completed

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Role: lead

NCT04224194Phase 3Completed

Auto-injector Real Life Handling in Patients

Role: lead

NCT03849313Phase 1Completed

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Role: lead

NCT03983876Phase 1Completed

PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)

Role: lead

NCT04453137Phase 3Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Role: lead

NCT03849404Phase 3Completed

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Role: lead

NCT03579823Phase 1Completed

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Role: lead

All 20 trials loaded